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1. Introduction 
Somatostatin inhibits insulin release in vivo [l-5 J 
and in vitro [6-lo] after exogenous administration. 
This inhibitory action was discovered at a time when 
only the hypothalamus and some extrahypothalamic 
areas in the central nervous system were known to 
contain somatostatin-producing cells [ 1 l-l 21. The 
suggestion that somatostatin might be of physiological 
importance in the regulation of insulin secretion was, 
therefore, based on the assumption that somatostatin 
is released into the peripheral circulation and trans- 
ported to the B-cell membrane at concentrations high 
enough to block secretion of insulin. 
The discovery that the D-cells of the islets of 
Langerhans react with antisomatostatin serum suggested 
local effects of the polypeptide via paracrine secretion. 
Somatostatin may indeed play a physiological role 
in the release of insulin [ 13- 171. We now present 
evidence that somatostatin is released from isolated 
rat pancreatic islets and that insulin and somatostatin 
release are interrelated. 
2. Materials and methods 
Fed, male Wistar rats (200-250 g) were used 
throughout the study. Bovine serum albumin was 
purchased from Behringwerke A. G. Marburg, FRG; 
“‘J-porcine insulin (specific activity 150-200 mCi/ 
mg) from Farbwerke Hoechst A. G. Frankfurt, FRG; 
crystalline rat insulin from NOVO Industri A. S. 
Copenhagen, Denmark; cyclic somatostatin from 
Serono, Freibrug, FRG; collagenase from Worthington 
Biochemical Co., USA. 
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Islets were isolated from rat pancreas bycollagenase 
2 h after intraperitoneal administration of 0.6 ml 
pilocarpin hydrochloride (2% w/v), as previously 
described [ 18,191, and incubated in batches of 10 in 
500 ~1 Krebs-Ringer bicarbonate buffer with glucose, 
mannoheptulose, epinephrine, rotenone and anti- 
mycin added as indicated in fig.1 and table 1. 
Insulin release into the medium was determined 
by radioimmunoassay with rat insulin as standard. 
Insulin release is expressed as ng/lO islets/45 min. 
Somatostatin was measured by radioimmunoassay 
using a rabbit antiserum produced by immunisation 
with cyclic somatostatin coupled to bovine serum 
albumin and ‘*‘J-tyrosilated somatostatin labelled 
by the chloramin-T procedure [20] and subsequently 
purified on CM-cellulose. The assay sensitivity is 
2 pg/mI and there is no cross-reaction with insulin, 
proinsulin, ghrcagon, gastrin or secretin. Further 
details of the assay procedure will be presented 
elsewhere [21] . 
3. Results 
The effect of glucose on somatostatin release from 
isolated rat pancreatic islets is shown in fig.1. In 
the presence of 5 mM glucose somatostatin release 
was 25 f 3 pg/lO islets/45 min and increased to 
46 f 5 pg/lO islets/45 mm when the glucose concen- 
tration was raised to 25 mM. The corresponding insulin 
release was 16.8 + 1 and 73.1 f 4 ng/lO islets/45 min, 
respectively (fig.1). 
Glucose-induced (25 mM) somatostatin release 
significantly decreased after addition of manno- 
heptulose (25 or 50 mM), epinephrine (2 I.cg/ml) or 
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5mM Glucose 
antimycin (5 fig/ml) plus rotenone (10 I.cg/ml). The 
inhibition of insulin release induced by these agents 
was greater than that of somatostatin (table 1). 
Fig.l. Effect of glucose on the release of somatostatin and 
insulin from isolated rat pancreatic islets. Incubations were 
in 500 ~1 Krebs-Ringer bicarbonate buffer, pH 7.4, 37”C, 
72 cycles/min, 1 mg BSA/ml. Mean values + S.E.M. are 
shown with the number of individual observations obtained 
from 10 rats in parentheses. Somatostatin release and insulin 
release is significantly higher in the presence of 25 mM 
glucose compared with 5 mM glucose (P<O.Ol). Values for 
P were calculated by the r-test based on non-paired 
comparisons. 
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4. Discussion 
The present data provide evidence that somato- 
statin is released from isolated islet tissue and that this 
release can be blocked. Somatostatin release, analogous 
to the secretion of insulin, is significantly higher in 
the presence of 25 mM glucose compared with 5 mM 
glucose (fig.1). This might indicate a direct stimula- 
tory effect of glucose on the secretory mechanism of 
somatostatin containing D-cells. Alternatively, insulin 
might have a direct stimulatory effect on the release 
mechanism of D-cells. This is supported by the obser- 
vation that somatostatin release is high if insulin 
release is high (at 25 mM glucose) and diminished if 
the stimulatory action of 25 mM glucose on insulin 
release is blocked by mannoheptulose, epinephrine or 
antimycin plus rotenone (fig.1, table 1). 
The observation that in streptozotocin-diabetic 
rats the somatostatin content in D-cells is increased 
[24] is compatible with the above concept, i.e., the 
somatostatin content might be high because stimula- 
tion of its release by insulin is diminished. 
Table 1 
Inhibition of glucose-induced somatostatin and insulin release from isolated rat pancreatic 
islets by mannoheptulose, epinephrine or antimycin plus rotenone. Incubations were as indicated 
in the legend to fig.1. Mean values f S.E.M. are shown with the number of individual observations 
obtained from 6 rats in parentheses. An asterisk indicates a significant difference from the 
respective control value (P<O.OS or less). Values for P were calculated by the r-test based on 
non-paired comparisons. 
_--____--_-____--i____--i==--==I==-------~------_ __-_-___ _=_____ ___ 
Glucose Bannoheptulose Epinephrine Antimycin + Rotenone IR-Insulin IR-Somatostatln 
(SW) hu) (kg/nl) (pg/ml) &/ml) bq/lO islets/45 mid (pg/lO lsletd45 nun) 
_______________________________-_______________-______________-_-____________________________._____._ 
25 -_ __ 68 i 6.0 (26) 56 t 6.5 (26) 
25 25 __ 20 t 1.6 (IQ)* 34 2 4.0 (19). 
25 50 __ 18 t 1.2 (:O)* 31 + 3.2 (20)' 
25 -_ __ 62 ?. 5.5 (20) 46 2 5.5 03) 
25 -_ 2 __ 14.2 1.5 (20)* 31 + 4.5 (20). 
25 -_ __ 63 + 3.6 (40) 48 2 6.0 (40) 
25 -_ 5 10 11 + 1.1 c401* 20 5 3.5 (40). 
===_=====_====____=_E====-- AxczZ= _ED=========== 
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The percent inhibition of insulin release is greater 
than that of somatostatin release, possibly because of 
a high ‘basal release’ of somatostatin, i.e., leakage 
from damaged D-cells. This is understandable b cause 
the D-cells are located in the periphery of the rat 
islets where damage during isolation is greatest. 
The physiological significance of endogenous 
somatostatin release for the secretion of insulin is 
unclear. Our data indicate a positive correlation 
between somatostatin levels and insulin levels. This 
also applies if the kinetics of glucose-induced somato- 
statin and insulin release are compared. 
Because of the wide distribution of somatostatin 
and its inhibitory effect on multiple secretory func- 
tions it has been suggested to be a candidate paracrine 
transmitter substance, i.e., the somatostatin containing 
cells are suggested to secrete their product not into 
the circulation but into the intracellular space, where 
it acts locally [23 J . Somatostatin sdegraded signifi- 
cantly during incubation with isolated rat islets and, 
if at all, is present at extremely low levels in the 
peripheral circulation (unpublished observations). 
This is entirely compatible with the above concept 
and indicates that the values for somatostatin given 
in this report must not be considered absolute but 
should be corrected for losses by enzymatic break- 
down. Inhibition of the enzymes responsible for 
degradation during incubation is at present being 
investigated. 
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